- GLP-1 receptor agonists are in Phase 2 or Phase 3 trials for at least six conditions beyond obesity and type 2 diabetes, with MASH and chronic kidney disease farthest along.
- SELECT trial cardiovascular data has anchored semaglutide's expansion into cardiometabolic medicine, creating precedent for payer coverage outside the obesity indication.
- Alzheimer's disease trials for semaglutide are actively enrolling in the EVOKE+ program, with results expected in 2027.
- Addiction medicine applications for GLP-1 agents are generating significant research interest, with early signals in alcohol use disorder, opioid craving reduction, and binge eating.
- Expanded indications would create new prescriber pools and clinical support staff requirements that extend well beyond obesity medicine and endocrinology.
The GLP-1 Pipeline Is Wider Than the Obesity Story
The public narrative around GLP-1 drugs in 2026 is dominated by obesity and the staffing boom around weight management clinics. But the scientific story is considerably broader. Semaglutide and tirzepatide are each being investigated across a range of conditions where the underlying biology of GLP-1 receptor signaling may be therapeutically relevant, and several of these investigations are in late-stage trials with near-term readout timelines.
Understanding this pipeline matters for two reasons. First, approved new indications would significantly expand the patient population eligible for GLP-1 therapy, with compounding effects on manufacturing demand, prescriber training needs, and clinical support infrastructure. Second, the therapeutic areas in question, liver disease, kidney disease, neurology, and addiction medicine, require clinical teams with specialist expertise that the current GLP-1 workforce does not fully possess.
By the numbers: Analysts estimate that approvals across MASH, CKD, and cardiovascular disease could expand the total addressable market for semaglutide-class drugs from approximately $50 billion today to over $130 billion by 2030, according to multiple investment bank forecasts published in early 2026.
Metabolic-Associated Steatohepatitis (MASH)
MASH, formerly called NASH, is the most advanced new indication in the GLP-1 pipeline. Semaglutide is in Phase 3 trials for MASH, and early results published in 2024 demonstrated meaningful reductions in liver inflammation and fibrosis in obese patients. The mechanism is plausible: GLP-1 signaling reduces hepatic lipid accumulation, inflammation, and insulin resistance, all of which drive MASH progression.
If Phase 3 data confirms the histological benefit signals, FDA approval for MASH would represent the largest single label expansion for the GLP-1 drug class since cardiovascular risk reduction. There are an estimated 5-6 million Americans with MASH-level liver disease, and current approved treatment options are extremely limited.
The clinical infrastructure for managing MASH patients differs from obesity medicine. Hepatologists, gastroenterologists, and liver transplant centers are the relevant specialists, and adding GLP-1 prescribing to their practice would require clinical education programs, new prior authorization pathways, and support staff trained in liver disease monitoring protocols.
Chronic Kidney Disease
The FLOW trial of semaglutide in patients with type 2 diabetes and chronic kidney disease demonstrated a significant reduction in kidney disease progression and kidney failure events. FDA has accepted a supplemental application for CKD as a new indication, and approval decisions are anticipated in mid-to-late 2026.
This indication would bring semaglutide into the nephrology prescribing space for the first time as a primary kidney protection therapy. The implications for care delivery are significant: nephrologists who have managed GLP-1 as a diabetes drug would become primary prescribers, dialysis clinics and CKD management programs would need to incorporate peptide therapy protocols, and clinical nurse specialists in nephrology would require training on GLP-1 management.
Manufacturing demand would increase substantially for a CKD approval, given the size of the CKD population and the chronic-use nature of the therapy.
Cardiovascular Disease Without Diabetes or Obesity
The SELECT trial established semaglutide's cardiovascular benefit in patients with established cardiovascular disease who had obesity but not diabetes. The approval FDA granted based on SELECT established a meaningful precedent: GLP-1 therapy is cardiovascular medicine, not just metabolic medicine.
Late-breaking trial data presented in early 2026 suggests that the cardiovascular mortality benefits seen in SELECT are durable over extended follow-up and are observed even in patients with relatively modest weight loss responses. This data is being used to argue that the cardiovascular benefit may be partially independent of weight reduction, which, if confirmed, would significantly broaden the prescribing rationale.
Cardiologists are increasingly being trained on GLP-1 prescribing through cardiology society CME programs, and several major health systems have embedded GLP-1 prescribing into cardiac rehabilitation and secondary prevention protocols.
Alzheimer's Disease
The EVOKE+ trial is evaluating semaglutide in patients with early Alzheimer's disease, with the hypothesis that GLP-1 receptor signaling has neuroprotective and anti-inflammatory effects in the brain. The trial enrolled approximately 3,000 patients across multiple sites internationally and is expected to report primary endpoints in 2027.
The scientific basis is observational data showing that diabetic patients on GLP-1 therapy have lower rates of dementia progression compared to those on other diabetes medications, and preclinical work demonstrating GLP-1 receptor expression in brain regions relevant to Alzheimer's pathology.
A positive EVOKE+ result would be transformational for the drug class, entering a therapeutic area with enormous unmet need, enormous patient population, and essentially no disease-modifying treatment currently available. The clinical and staffing infrastructure required to deliver GLP-1 therapy to Alzheimer's patients would be entirely different from weight management clinic operations.
Addiction Medicine
Among the emerging new indications attracting scientific attention, addiction medicine applications may be the most surprising. Multiple research groups have published data suggesting that GLP-1 receptor agonists reduce cravings and consumption in alcohol use disorder, opioid dependence, and nicotine dependence in both animal models and early human studies.
Several Phase 2 trials in alcohol use disorder are actively enrolling in 2026, and observational claims data analyses showing reduced alcohol-related hospitalizations in patients initiating semaglutide have generated significant interest. The proposed mechanism involves GLP-1 receptor activity in the mesolimbic dopamine system, the same reward circuitry implicated in addictive behavior.
An approved addiction medicine indication would bring GLP-1 drugs into psychiatry, addiction medicine, and primary care contexts with no current GLP-1 prescribing infrastructure, creating a new wave of clinician education and clinical support needs.
PCOS and Reproductive Endocrinology
Polycystic ovary syndrome affects approximately 10% of women of reproductive age and is strongly linked to insulin resistance and metabolic dysfunction. GLP-1 therapy has shown efficacy in improving PCOS symptoms, menstrual regularity, and metabolic markers in multiple smaller studies, and formal clinical development programs are advancing.
The reproductive endocrinology and fertility clinic space currently has limited GLP-1 prescribing infrastructure. Approval for a PCOS indication would bring a new prescriber population and clinical support staff context into the GLP-1 ecosystem.
What the Pipeline Means for the Peptide Workforce
The common thread across all these pipeline programs is that each approved indication would bring a new specialist prescriber group, a new patient population with specific monitoring needs, and a new set of clinical support staff requirements into the GLP-1 treatment landscape.
The current peptide workforce, concentrated in obesity medicine, primary care, and endocrinology, would need to expand into hepatology, nephrology, cardiology, neurology, addiction medicine, and reproductive endocrinology to serve the full indication expansion. That expansion will not happen uniformly or immediately, but the pipeline data visible in 2026 makes clear that the trajectory is toward a GLP-1 drug class that serves a broad slice of chronic disease medicine, not a specialized obesity therapy market.
For hiring managers and clinical staffing professionals, the near-term implication is to watch CKD and MASH approvals closely. These are the most likely near-term label expansions, and both would create immediate hiring pressure in specialist clinical settings that are not currently part of the peptide clinic talent conversation.
PeptideStaff tracks clinical pipeline developments and their workforce implications across the peptide therapeutics industry. See more at PeptideStaff News.
Topics
PeptideStaff Editorial Team
Healthcare Staffing Specialists
Collective expertise across clinical staffing, regulatory compliance, and peptide industry operations
Our editorial team combines backgrounds in healthcare recruitment, peptide research, and clinical operations to produce accurate, actionable staffing and industry guidance for peptide businesses.
Reviewed by the PeptideStaff Editorial Team, April 2026